World's Best Scientists 2026 revealed!
Richard G. Langley

Richard G. Langley

D-Index & Metrics

Medicine

D-Index
83
Citations
32165
World Ranking
15434
National Ranking
644

Overview

Richard G. Langley is affiliated with Dalhousie University in Canada. Their research primarily focuses on medicine, immunology, and microbiology, with significant contributions in immunology, dermatology, pathology and forensic medicine, pediatrics, perinatology and child health, and physiology.

The scientist's work covers a range of topics within dermatology and immune-related diseases. Major areas of study include psoriasis treatment and pathogenesis, dermatology and skin diseases, autoimmune bullous skin diseases, pharmaceutical studies and practices, asthma and respiratory diseases, health systems, economic evaluations, quality of life, and urticaria and related conditions.

Frequent publication venues for Richard G. Langley include the Journal of the American Academy of Dermatology, SKIN The Journal of Cutaneous Medicine, British Journal of Dermatology, Dermatology and Therapy, and JAMA Dermatology.

Co-authors who have collaborated multiple times with Langley are Mark Lebwohl, Andrew Blauvelt, Richard B. Warren, Kristian Reich, and Bruce Strober.

Some recent notable papers published by or involving Richard G. Langley are:

  • Bimekizumab versus Secukinumab in Plaque Psoriasis, 2021, New England Journal of Medicine
  • Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial, 2021, The Lancet
  • Bimekizumab versus Adalimumab in Plaque Psoriasis, 2021, New England Journal of Medicine
  • Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis, 2020, JAMA Dermatology
  • A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial, 2020, British Journal of Dermatology

Best Publications

  • Secukinumab in plaque psoriasis--results of two phase 3 trials.

    Richard G. Langley;Boni E. Elewski;Mark Lebwohl;Kristian Reich

  • Psoriasis: epidemiology, clinical features, and quality of life

    R G B Langley;G G Krueger;C E M Griffiths

  • A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

    Gerald G. Krueger;Richard G. Langley;Craig Leonardi;Newman Yeilding

  • Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

    Alan Menter;Stephen K. Tyring;Kenneth Gordon;Alexa B. Kimball

  • Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    Mark Lebwohl;Bruce Strober;Alan Menter;Kenneth Gordon

  • Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

    Jean-Hilaire Saurat;G. Stingl;L. Dubertret;K. Papp

  • Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Kenneth B Gordon;Jean-Frederic Colombel;Dana S Hardin

  • Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment

    Richard G. Langley;Charles N. Ellis

  • Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

    Kenneth B. Gordon;Richard G. Langley;Craig Leonardi;Darryl Toth

  • Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Kim Papp;Kristian Reich;Craig L. Leonardi;Leon Kircik

  • Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

    Mark G. Lebwohl;Hervé Bachelez;Jonathan Barker;Giampiero Girolomoni

  • Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

    K.A. Papp;R.G. Langley;B. Sigurgeirsson;M. Abe

  • Etanercept treatment for children and adolescents with plaque psoriasis.

    Amy S. Paller;Elaine C. Siegfried;Richard G. Langley;Alice B. Gottlieb

  • An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis

    Mark Lebwohl;Enno Christophers;Richard Langley;Jean P. Ortonne

  • Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.

    Lawrence F. Eichenfield;Anne W. Lucky;Mark Boguniewiczc;Richard G.B. Langley

  • A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†

    K.A. Papp;K. Reich;C. Paul;A. Blauvelt

  • Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis

    Stephen Tyring;Kenneth B. Gordon;Yves Poulin;Richard G. Langley

  • Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy

    Jon M. Hanifin;Mark R. Ling;Richard Langley;Debra Breneman

  • Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

    K.A. Papp;A. Menter;B. Strober;R.G. Langley

  • Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials

    K.A. Papp;M.A. Menter;M. Abe;B. Elewski

Frequent Co-Authors

Kim Papp
Kim Papp Probity Medical Research
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Kenneth B. Gordon
Kenneth B. Gordon Medical College of Wisconsin
Kristian Reich
Kristian Reich University of Göttingen
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Carle Paul
Carle Paul Federal University of Toulouse Midi-Pyrénées
Craig L. Leonardi
Craig L. Leonardi Saint Louis University
Christopher E.M. Griffiths
Christopher E.M. Griffiths University of Manchester
Alan Menter
Alan Menter Texas A&M University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As interest grows in studying Medicine in the USA, many students are also considering related online degrees and alternative career pathways in healthcare. The flexibility of online programs can make advanced qualifications more accessible than ever, especially for those with busy schedules or work commitments.

For nurses seeking to elevate their careers, the fastest dnp online program options provide a way to quickly achieve a Doctor of Nursing Practice. Those looking for more manageable admission requirements or workloads can explore dnp online programs designed with efficiency and support in mind.

If you’re beginning your healthcare journey, a lpn program can be completed online and lead directly into practical nursing roles in a relatively short period. For those interested in mental health, some of the shortest online pmhnp programs offer a fast-track route to becoming a Psychiatric Mental Health Nurse Practitioner.

These programs combine convenience with rigorous training, making them ideal options for anyone wishing to advance or pivot their healthcare career without committing to traditional, on-campus education.

Best Scientists Citing Richard G. Langley

Trending Scientists

Recently Published Articles